Q32 Bio Inc(QTTB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:10 PM ET (Korea 10/29 05:10)
Full metrics table
| Index | - | P/E | 3.02 | EPS (ttm) | 3 | Insider Own | 35.34% | Shs Outstand | 23.7M | Perf Week | 4.5% |
| Market Cap | 0.27B | Forward P/E | - | EPS next Y | -47.98% | Insider Trans | 54.88% | Shs Float | 19.3M | Perf Month | -4.93% |
| Enterprise Value | 0.17B | PEG | - | EPS next Q | -0.33 | Inst Own | 50.96% | Short Float | 29.36% | Perf Quarter | -41.77% |
| Income | 0.03B | P/S | 5.02 | EPS this Y | -161.21% | Inst Trans | 5.66% | Short Ratio | 7.85 | Perf Half Y | 64.73% |
| Sales | 0.05B | P/B | 2.03 | EPS next 5Y | - | ROA | 37.13% | Short Interest | 5.65M | Perf YTD | 172.89% |
| Book/sh | 4.46 | P/C | 2.54 | EPS past 3/5Y | - | ROE | 72.14% | 52W High | -61.56% ($23.57) | Perf Year | 253.91% |
| Cash/sh | 3.57 | P/FCF | - | Sales past 3/5Y | 155.87% 81.85% | ROIC | 30.58% | 52W Low | 375.59% ($1.90) | Perf 3Y | -50.65% |
| Dividend Est. | - | EV/EBITDA | 7.73 | EPS Y/Y TTM | 169.98% | Gross Margin | 99.34% | Volatility(W/M) | 4.82% 8.58% | Perf 5Y | -91.08% |
| Dividend TTM | - | EV/Sales | 3.14 | Sales Y/Y TTM | - | Oper. Margin | 39.94% | ATR (14) | 0.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 20.28 | EPS Q/Q | 43.46% | Profit Margin | 62.87% | RSI (14) | 49.88 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 20.28 | Sales Q/Q | - | SMA20 | 9.01% ($8.31) | Beta | 0.48 | Target Price | $39.43 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/5 | SMA50 | -15.53% ($10.73) | Rel Volume | 0.57 | Prev Close | $8.71 |
| Employees | 24 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | 18.79% -100% | SMA200 | -1.33% ($9.18) | Avg Volume(3M) | 0.72M | Price | $9.06 |
| IPO | 2018/3/28 | Option/Short | Yes/Yes | Trades | 2660 | Volume | 409,212 | Change | 4.02% |
🧬 Q32 Bio (QTTB) is a clinical-stage biotech company developing immune-modulating antibodies. Its lead candidate, bempikibart, is an antibody targeting the interleukin-7 receptor and is currently in Phase 2 clinical trials for alopecia areata, an autoimmune hair loss disorder. The stock price is heavily driven by the value of its drug pipeline, which is typical of a clinical-stage company.
Over the past 1 year, roughly in the middle
62% below its 1-year high.
Traded less than usual. That is 57% of its average volume.
QTTB makes money exceptionally well
Of every $100 in sales, $39.94 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -161.2% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $773. Peers typically go for $2,136.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.1%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Short interest is a burden
29.4% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #272 of 594 in the industry
Based on market cap of $270M.
FAQ
What kind of company is QTTB?
QTTB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of QTTB?
The market cap of QTTB is approximately $270M, ranking 3,766 within its sector.
What is the P/E ratio of QTTB?
QTTB has a P/E ratio of approximately 3.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for QTTB?
QTTB has recorded a 52-week high of $23.57 and a low of $1.90.
